Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M108Revenue (TTM) $M1.6Net Margin (%)-1,330.1Altman Z-Score-8.1
Enterprise Value $M79.3EPS (TTM) $-0.7Operating Margin %-1,344.1Piotroski F-Score2
P/E(ttm)--Beneish M-Score3.5Pre-tax Margin (%)-1,339.6Higher ROA y-yN
Price/Book5.210-y EBITDA Growth Rate %--Quick Ratio5.9Cash flow > EarningsY
Price/Sales58.75-y EBITDA Growth Rate %--Current Ratio5.9Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %-376.2ROA % (ttm)-71.1Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-103.5Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M34.2ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with PSDV

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
PSDVKen Fisher 2015-09-30 Buy $3.49 - $4.47
($3.92)
$ 3.17-19%New holding12,057
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

PSDV is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


PSDV: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Ross Leonard SVice President, Finance 2016-01-04Sell5,000$4.7-32.55view
Ross Leonard SVice President, Finance 2015-12-22Sell33,950$5.39-41.19view
Ashton PaulPresident & CEO 2015-12-22Sell120,000$5.39-41.19view
Ross Leonard SVice President, Finance 2015-12-01Sell1,050$4.06-21.92view
Ross Leonard SVice President, Finance 2015-08-03Sell5,000$4.05-21.73view
Ashton PaulPresident & CEO 2014-10-01Sell10,000$4.27-25.76view
Ashton PaulPresident & CEO 2014-09-02Sell10,000$4.78-33.68view
Ashton PaulPresident & CEO 2014-08-01Sell10,000$4.37-27.46view
Ashton PaulPresident & CEO 2014-07-01Sell10,000$4.32-26.62view
Ashton PaulPresident & CEO 2014-06-19Sell7,000$4-20.75view

Quarterly/Annual Reports about PSDV:

    News about PSDV:

    Articles On GuruFocus.com
    Weekly CEO Sales Highlight: pSivida Corp., Equity Residential, Ciena Corp., Sabre Corp. Dec 28 2015 
    pSivida Ltd. Reports Operating Results (10-Q) Feb 10 2011 
    pSivida Ltd. Reports Operating Results (10-Q) Nov 09 2010 
    pSivida Ltd. Reports Operating Results (10-K) Sep 27 2010 
    pSivida Ltd. Reports Operating Results (10-Q) May 13 2010 
    pSivida Ltd. Reports Operating Results (10-Q) Feb 12 2010 
    pSivida Ltd. Reports Operating Results (10-Q) Nov 13 2009 
    pSivida Ltd. Reports Operating Results (10-K) Sep 25 2009 
    pSivida Ltd. Reports Operating Results (10-Q) May 13 2009 
    pSivida Ltd. Reports Operating Results (10-Q) Feb 11 2009 

    More From Other Websites
    pSivida to Present at the Ladenburg Thalmann Annual Healthcare Conference Sep 22 2016
    PSIVIDA CORP. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... Sep 20 2016
    pSivida Reports Inducement Awards to New President and Chief Executive Officer Sep 20 2016
    pSivida Reports Inducement Awards to New President and Chief Executive Officer Sep 20 2016
    PSIVIDA CORP. Financials Sep 17 2016
    Watertown's pSivida appoints new CEO to focus on commercialization Sep 15 2016
    pSivida Implements Leadership Change -- Nancy Lurker Named as President and CEO Sep 15 2016
    pSivida Implements Leadership Change -- Nancy Lurker Named as President and CEO Sep 15 2016
    PSIVIDA CORP. Files SEC form 10-K, Annual Report Sep 13 2016
    Edited Transcript of PSDV earnings conference call or presentation 12-Sep-16 8:30pm GMT Sep 13 2016
    PSivida reports 4Q loss Sep 12 2016
    PSivida reports 4Q loss Sep 12 2016
    pSivida Corp. Provides Company Update and Reports Fourth Quarter and FY 2016 Results Sep 12 2016
    PSIVIDA CORP. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Sep 12 2016
    pSivida Corp. Provides Company Update and Reports Fourth Quarter and FY 2016 Results Sep 12 2016
    Q4 2016 pSivida Corp Earnings Release - After Market Close Sep 12 2016
    pSivida Corp. Announces Fourth Quarter and Fiscal Year 2016 Financial Results Release Date and... Sep 01 2016
    pSivida Corp. Announces Fourth Quarter and Fiscal Year 2016 Financial Results Release Date and... Sep 01 2016
    pSivida Announces 13 New Patents Issued or Allowed Aug 29 2016
    pSivida Announces 13 New Patents Issued or Allowed Aug 29 2016
    Topline Results from First Phase 3 Trial of pSivida’s Medidur™ Presented at ASRS Annual Meeting Aug 15 2016
    Primary Endpoint Met in pSivida's Utilization Study of New Medidur™ Inserter with Smaller Diameter... Aug 09 2016
    Primary Endpoint Met in pSivida’s Utilization Study of New Medidur™ Inserter with Smaller... Aug 09 2016
    pSivida Names Dario Paggiarino, M.D. as Chief Medical Officer Aug 03 2016
    pSivida Names Dario Paggiarino, M.D. as Chief Medical Officer Aug 03 2016
    pSivida Corp and Hospital for Special Surgery Innovation Center Announce Opening of IND for... Aug 01 2016
    pSivida Corp and Hospital for Special Surgery Innovation Center Announce Opening of IND for... Aug 01 2016
    pSivida Corp.: Strong price momentum but will it sustain? Jul 27 2016
    pSivida's Medidur™ Maintains Same High Statistical Significance in Primary Endpoint through 12... Jul 27 2016
    pSivida's Medidur™ Maintains Same High Statistical Significance in Primary Endpoint through 12... Jul 27 2016
    ETF’s with exposure to pSivida Corp. : July 20, 2016 Jul 20 2016
    Data Shows pSivida’s Tethadur™ Provides Prolonged, Sustained Release of Avastin® With High Drug... Jul 20 2016
    pSivida Corp. Announces Plan to Consolidate all Research and Development in Current U.S. Facility Jul 15 2016
    Investigator-Sponsored Phase 2 Study Results Show pSivida's Medidur® Fully Controlled Uveitis for... Jul 14 2016
    pSivida Announces Poster and Oral Presentation on Controlled Release of Avastin® from Tethadur™... Jul 08 2016
    pSivida Announces Successful Completion of Two Preclinical Studies of Durasert™ Sustained-Release... Jul 05 2016
    PSivida reports 3Q loss May 05 2016
    pSivida Corp. Provides Company Update and Reports Third Quarter FY 2016 Results May 05 2016
    pSivida CEO to Present at 2016 International Symposium of Ocular Pharmacology and Therapeutics May 04 2016
    pSivida's Medidur for Posterior Uveitis Granted Orphan Drug Designation in Europe May 02 2016
    pSivida Corp. Announces Third Quarter Fiscal Year 2016 Financial Results Release Date and Conference... Apr 27 2016
    pSivida to Present at the Sidoti Spring 2016 Emerging Growth Convention Mar 24 2016
    PSivida reports 2Q loss Feb 08 2016
    pSivida Corp Announces Second Quarter Fiscal Year 2016 Financial Results Release Date and Conference... Feb 01 2016
    pSivida CEO to Present at 18th Annual Bio CEO & Investor Conference February 9 Jan 28 2016
    PSivida reports 1Q loss Nov 05 2015
    PSivida reports 4Q loss Sep 09 2015
    PSivida reports 3Q loss May 08 2015
    PSivida reports 2Q loss Feb 05 2015

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)